An announcement from Fresenius Medical Care ( (FMS) ) is now available.
Fresenius Medical Care AG has announced its Annual General Meeting scheduled for May 22, 2025, in Frankfurt, Germany. The meeting will address several key resolutions, including the approval of financial statements for 2024, the allocation of distributable profit with a proposed dividend of EUR 1.44 per share, and the election of PricewaterhouseCoopers as the auditor for fiscal year 2025. Additionally, the company plans to create a new authorized capital structure to simplify its capital management, enhancing its flexibility for future growth.
Spark’s Take on FMS Stock
According to Spark, TipRanks’ AI Analyst, FMS is a Outperform.
Fresenius Medical Care’s stock is rated at 72, driven by stable financial health, effective cash flow management, and strategic progress highlighted in their earnings call. The stock’s valuation is reasonable, and technical indicators suggest a slight upward momentum. However, reliance on debt and challenges in the U.S. dialysis market present risks.
To see Spark’s full report on FMS stock, click here.
More about Fresenius Medical Care
Fresenius Medical Care AG is a leading provider in the healthcare industry, specializing in the production and supply of dialysis products and services. The company focuses on providing comprehensive care for individuals with chronic kidney failure, operating a network of dialysis clinics worldwide.
YTD Price Performance: 5.73%
Average Trading Volume: 316,810
Technical Sentiment Signal: Buy
Current Market Cap: $13.02B
For a thorough assessment of FMS stock, go to TipRanks’ Stock Analysis page.